<DOC>
	<DOCNO>NCT00598650</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy E2020 patient Dementia Lewy Bodies ( DLB ) .</brief_summary>
	<brief_title>A Long-term , Extension Study E2020 Patients With Dementia With Lewy Bodies</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients diagnose probable Dementia Lewy Bodies ( DLB ) accord diagnostic criterion DLB . 2 . Patients complete Phase II doubleblind study ( E2020J081431 ) . 3 . Patients caregiver submit write consent cooperative involvement study , routinely stay patient 3 day week ( least 4 hour day ) , provide patient ' information necessary study , assist treatment compliance escort patient require visit study institution . Exclusion criterion : 1 . Patients complication serious neuropsychiatric disease ( ) stroke , brain tumor , schizophrenia , epilepsy , normal pressure hydrocephalus , mental retardation , brain trauma unconsciousness , and/or underwent brain surgery cause unsolved deficiency . 2 . Patients severe complication cardiovascular , hepatic , renal , hematological , diseases unable secure safety . 3 . Pregnant lactate woman , woman willing become pregnant later 1 month schedule study completion . 4 . Patients severe extrapyramidal disorder ( Hoehn Yahr stag score great IV ) . 5 . Patients whose systolic blood pressure le 90 mmHg pulse rate le 50 beats/min .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Lewy Body Disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Phase II</keyword>
	<keyword>E2020</keyword>
	<keyword>donepezil hydrochloride</keyword>
</DOC>